SEC Comment Letter for Oyster Point Pharma, Inc. (CIK 0001720725) — May 4, 2020

Oyster Point Pharma, Inc. (CIK 0001720725)
Date: May 4, 2020 · CIK: 0001720725 · Accession: 0000000000-20-003880

View on Edgar

AI Filing Summary & Sentiment

Date

May 4, 2020

Author

Not clearly detected

Form

UPLOAD

Company

Oyster Point Pharma, Inc. (CIK 0001720725)

Letter

United States securities and exchange commission logo May 4, 2020 Jeffrey Nau, Ph.D., M.M.S. President and Chief Executive Officer Oyster Point Pharma, Inc. 202 Carnegie Center, Suite 109 Princeton, New Jersey 08540 Re:Oyster Point Pharma, Inc. Draft Registration Statement on Form S-1 Filed April 27, 2020 CIK No. 0001720725 Dear Dr. Nau: This is to advise you that we do not intend to review your registration statement. We request that you publicly file your registration statement no later than 48 hours prior to the requested effective date and time. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Chris Edwards at (202) 551-6761 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Divakar Gupta

Show Raw Text

United States securities and exchange commission logo
May 4, 2020
Jeffrey Nau, Ph.D., M.M.S.
President and Chief Executive Officer
Oyster Point Pharma, Inc.
202 Carnegie Center, Suite 109
Princeton, New Jersey 08540
Re:Oyster Point Pharma, Inc.
Draft Registration Statement on Form S-1
Filed April 27, 2020
CIK No. 0001720725
Dear Dr. Nau:
            This is to advise you that we do not intend to review your registration statement.
            We request that you publicly file your registration statement no later than 48 hours prior
to the requested effective date and time. Please refer to Rules 460 and 461 regarding requests for
acceleration. We remind you that the company and its management are responsible for the
accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or
absence of action by the staff.
            Please contact Chris Edwards at (202) 551-6761 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc:       Divakar Gupta

SecProbe.io